GENEVA — On 7 October 2026, the World Health Organization issued its first global guidelines on managing obesity in children and adolescents, recommending structured support for healthy eating, physical activity, and behaviour change as the foundation of care, advising against weight-loss medicines, surgery, or devices for children aged 0 to 9, and allowing medicines for adolescents aged 10 to 19 only after supervised lifestyle programmes have not worked — guidance that arrives as an estimated 170 million children and adolescents worldwide live with obesity.
Illustration: Children playing actively outdoors in a park with fruit and vegetables nearby, representing healthy childhood habits.
What Happened
The World Health Organization launched two new guidelines on 7 October 2026 on the integrated management of obesity in children and adolescents, setting out how health systems and health workers can deliver timely, evidence-based, and people-centred care. The guidelines address what WHO describes as an important gap in global guidance on obesity care, and together with its existing recommendations for adults they form a set of evidence-based recommendations across the life course, from childhood through adolescence to adulthood.
The core recommendation is unambiguous: structured dietary, physical-activity, and behaviour-changing interventions, delivered individually or as part of a multimodal programme, are strongly recommended as the foundation of care. Digital health interventions receive a conditional recommendation, with parent or caregiver supervision. For children aged 0 to 9 years, WHO does not recommend pharmacological treatment, bariatric surgery, or weight-loss devices. For adolescents aged 10 to 19 years, approved medicines may be considered only when a supervised multimodal lifestyle programme has not achieved the desired results, and bariatric surgery may be considered only under strict conditions for adolescents with severe obesity.
WHO also emphasises mental health alongside physical health. The guidelines note that anxiety, depression, emotional dysregulation, and low self-esteem may contribute to unhealthy eating patterns, physical inactivity, and social withdrawal, and that children and adolescents living with obesity may experience stigma, discrimination, and bullying. Care, WHO says, should target health, functioning, and well-being — not weight alone — and should involve families, with continuing follow-up adapted to each child. Assessment should consider individual circumstances and health rather than body mass index alone, according to the European Association for the Study of Obesity, which participated in the launch and welcomed the guidance.
The guidelines were covered in detail by medical and health media in the days after launch, and summarised in the Journal of the American Medical Association (JAMA) on 23 October 2026. JAMA's summary notes that WHO recommends children and adolescents use structured dietary, physical-activity, and behaviour-changing interventions, does not recommend drug treatment or bariatric surgery for children aged 9 or younger, and advises that for adolescents aged 10 to 19, medication be used only if a lifestyle programme is unsuccessful, with surgery only for severe obesity under strict conditions. Dr. Luz María De Regil, director of WHO's Department of Nutrition and Food Safety, was reported as saying that the foundation of obesity care for children and adolescents is not medicine or surgery, but access to comprehensive support, and that there is currently not enough evidence on GLP-1 drugs in young people for WHO to recommend them more broadly.
Background
The scale of the problem explains why WHO acted now. In 2024, an estimated 400 million children and adolescents aged 5 to 19 were overweight, including 170 million living with obesity — 70 million aged 5 to 9 and 100 million aged 10 to 19, according to WHO figures cited in the launch coverage. The prevalence of obesity in this age group has quadrupled since 1990, rising from 2% to 8%. Obesity is described by WHO as a chronic, relapsing disease that can be managed with effective care; its consequences can begin early in life, increasing the risk of type 2 diabetes, cardiovascular disease, and other noncommunicable diseases later on.
The guidelines arrive at a moment of rapid change in obesity treatment, and some tension with it. Glucagon-like peptide-1 (GLP-1) receptor agonists — the class that includes Wegovy — have been prescribed increasingly to adolescents in recent years, while bariatric surgery in that age group has declined, according to research cited by JAMA. A JAMA Pediatrics research letter reported by Becker's Hospital Review found that among patients aged 13 to 25 treated for obesity, exclusive GLP-1 use rose from 88.2% to 96.1% between 2022 and early 2026, while completion of bariatric surgery fell from 11.6% to 3.7%. Use among US children aged 8 to 11 with obesity rose from 0.03% in 2019 to 9.3% in 2026, according to the same coverage. In September 2026, Novo Nordisk reported that two out of every five young children who took Wegovy in a clinical trial lost enough weight to no longer be classified as having obesity — the first trial to test the drug in children younger than 12.
WHO's position is not a rejection of medicines, but a sequencing rule: lifestyle support first, medicines only if that fails, surgery only in narrow circumstances. The agency says it may revise its guidance as trial results emerge, particularly on GLP-1 drugs in young people, where evidence remains limited. That caution reflects a genuine scientific gap: most obesity drug trials have been conducted in adults, and long-term effects in growing children — including on nutrition, growth, and bone health — are less well understood. Some findings suggest GLP-1 medicines in adolescents may be linked to nutritional deficiencies, a concern noted in JAMA's coverage.
The guidelines also go beyond clinics into policy. WHO calls for fiscal and regulatory measures, and action across education, urban planning, transport, and social protection: front-of-pack labelling of foods high in fat, sugar, and salt; school nutrition and physical-education standards; and urban design that makes walking, cycling, and play safe. The message is that childhood obesity is shaped by interacting environmental, social, biological, and behavioural factors, and that health systems alone cannot solve a problem created in food environments, school canteens, advertising, and neighbourhoods designed around cars rather than play.
Illustration: A doctor talking warmly with a child and parent in a bright clinic, representing supportive childhood health care.
Why It Matters
For families, the guidelines offer a clear international reference point in a confusing and often commercialised landscape. Parents searching for help for a child with obesity encounter conflicting advice, aggressive marketing of supplements and programmes, and, increasingly, questions about whether a weight-loss drug is appropriate for a child. WHO's answer — start with structured, supervised support for food, activity, and behaviour; involve the family; protect mental health; do not reach for drugs or surgery in young children — gives clinicians and families a shared framework for those conversations. It also legitimises asking health systems to provide that support, rather than leaving families to navigate the problem alone.
For health systems, the guidelines set an implementation challenge. Structured multimodal programmes require trained primary-care workers, dietitians, physical-activity support, and mental-health input, with referral to specialists where needed — capacity that many countries, especially low- and middle-income ones, do not yet have at scale. The European Association for the Study of Obesity emphasised that care should sit within primary health services, with assessment based on individual circumstances rather than BMI alone. Whether governments fund that capacity — training workers, financing family-based programmes, and taking on the commercial food environment — will determine whether the guidelines change practice or remain aspirational. As one analysis of the launch put it, the guidelines will be judged by implementation, and the tasks involved are far harder than writing a prescription.
For policymakers, the guidelines strengthen the case for prevention as well as treatment. If 170 million children and adolescents already live with obesity, treatment alone cannot reverse the trend; the food environment, school meals, marketing to children, and opportunities for safe play must also change. Countries facing a double burden — persistent undernutrition alongside rising overweight, as in India, where an estimated 12.5 million children and adolescents aged 5 to 19 lived with obesity in 2022 — face particularly complex choices, balancing food security against the regulation of unhealthy foods. WHO's policy recommendations give those governments an evidence-based menu, but the political battles over labelling, advertising, and school food standards will still have to be fought country by country.
There is also an important caveat about scope. WHO guidelines are advisory, not binding, and national practice varies. In the United States, for example, paediatricians generally follow the American Academy of Pediatrics, whose recommendations for teenagers differ in important ways from WHO's more conservative sequencing. Families should therefore treat WHO's guidance as a framework for discussion with their own clinician, not as individual medical advice — and clinicians will weigh it alongside national guidelines, the child's circumstances, and the evidence available for each treatment option.
What Happens Next
Implementation is now the central question. WHO held a virtual launch event on 7 October 2026 presenting the recommendations and the evidence behind them, with a panel of experts. The next steps fall to national health ministries: adapting the guidelines into national protocols, training primary-care workers, funding family-based programmes, and deciding how to regulate the food environment. Organisations such as the European Association for the Study of Obesity, which welcomed the framework, are expected to support that translation in their regions.
Research will also shape what comes next. WHO has signalled that its guidance may be revised as new trial results emerge on GLP-1 drugs in children and adolescents, and the September 2026 Wegovy trial in children under 12 is likely to be scrutinised closely as fuller data become available. Longer-term studies on safety, growth, nutrition, and mental health in young people taking obesity medicines will be decisive for any future shift in the sequencing rules.
For the millions of families already living with childhood obesity, the most meaningful test will be practical: whether a parent who seeks help finds a supportive, non-stigmatising service that offers structured help with food, activity, and behaviour — and whether schools, neighbourhoods, and food policies make healthy choices easier rather than harder. WHO's first global guidelines on childhood obesity set that standard. Meeting it will take years of investment, but the direction is now unmistakable: care that starts with support, protects mental health, involves families, and reserves medicines and surgery for the cases where they are genuinely needed.
Illustration: A school lunch tray with fresh vegetables, fruit and whole grains, representing school nutrition policy.
Sponsored: explore today's featured sponsored offers
FAQ
What did WHO publish on 7 October 2026?
Its first global guidelines on the integrated management of obesity in children and adolescents — two documents covering children aged 0 to 9 and adolescents aged 10 to 19 — setting out how health systems can deliver evidence-based, people-centred care.
What does WHO recommend as the foundation of care?
Structured dietary, physical-activity, and behaviour-changing interventions, delivered individually or as part of a multimodal programme, with digital health tools conditionally recommended under parent or caregiver supervision.
Does WHO recommend weight-loss drugs or surgery for young children?
No. WHO does not recommend pharmacological treatment, bariatric surgery, or weight-loss devices for children aged 0 to 9 years.
When can medicines or surgery be considered for adolescents?
For adolescents aged 10 to 19, approved medicines may be considered only after a supervised multimodal lifestyle programme has not achieved the desired results, and bariatric surgery only under strict conditions for severe obesity.
How many children and adolescents live with obesity?
WHO estimates that in 2024, 170 million children and adolescents aged 5 to 19 lived with obesity, out of 400 million who were overweight; prevalence in this age group has quadrupled since 1990, from 2% to 8%.
Sources
- World Health Organization, "Launch of WHO guidelines: integrated management of obesity in children and adolescents", 7 October 2026 — https://www.who.int/news-room/events/detail/2026/10/07/default-calendar/launch-of-who-guidelines--integrated-management-of-obesity-in-children-and-adolescents
- JAMA, "WHO Publishes First Guidelines for Managing Obesity in Children", published online 23 October 2026 — https://jamanetwork.com/journals/jama/fullarticle/2855963
- Becker's Hospital Review, "WHO issues 1st youth obesity guidelines, addresses weight-loss drugs", 7 October 2026 — https://www.beckershospitalreview.com/glp-1s/who-issues-1st-youth-obesity-guidelines-addresses-weight-loss-drugs/
- Medical Daily, "WHO's First Child Obesity Guidelines Advise Against Weight-Loss Drugs, Surgery and Devices for Children Under 10", 7 October 2026 — https://www.medicaldaily.com/who-child-obesity-guidelines-no-drugs-surgery-under-10-479672
Comments
Post a Comment